A M55V Polymorphism in the SUMO4 Gene is Associated with a Reduced Prevalence of Diabetic Retinopathy in Patients with Type 1 Diabetes
暂无分享,去创建一个
A. Hamann | A. Bierhaus | P. Nawroth | M. Morcos | P. Humpert | A. Schlotterer | J. Tafel | Gottfried Rudofsky
[1] Edgar Erdfelder,et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.
[2] M. Hsieh,et al. SUMO4 M55V Variant Is Associated With Diabetic Nephropathy in Type 2 Diabetes , 2007, Diabetes.
[3] Paul Mitchell,et al. The eye in hypertension , 2007, The Lancet.
[4] T. Ogihara,et al. Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes. , 2005, Diabetes.
[5] K. Wellen,et al. Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.
[6] A. Aljada,et al. Contemporary Reviews in Cardiovascular Medicine Metabolic Syndrome A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation , 2022 .
[7] K. Bohren,et al. A M55V Polymorphism in a Novel SUMO Gene (SUMO-4) Differentially Activates Heat Shock Transcription Factors and Is Associated with Susceptibility to Type I Diabetes Mellitus* , 2004, Journal of Biological Chemistry.
[8] M. Matunis,et al. SUMO Modification of Heterogeneous Nuclear Ribonucleoproteins , 2004, Molecular and Cellular Biology.
[9] J. Schneider,et al. A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[10] A. Hamann,et al. New treatments for diabetic neuropathy: Pathogenetically oriented treatment , 2003, Current diabetes reports.
[11] H. Hammes,et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.
[12] Timothy S Kern,et al. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. , 2002, Diabetes.
[13] Factors in Development of Diabetic Neuropathy: Baseline Analysis of Neuropathy in Feasibility Phase of Diabetes Control and Complications Trial (DCCT) , 1988, Diabetes.
[14] Yan Zhang,et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. , 2004, Nature genetics.
[15] R. Gaynor,et al. IkappaB kinases: key regulators of the NF-kappaB pathway. , 2004, Trends in biochemical sciences.
[16] Csaba Szabó,et al. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. , 2004, Diabetes.
[17] S. Schiekofer,et al. The role of oxidative stress and NF‐κB activation in late diabetic complications , 1999, BioFactors.
[18] L. Vuillard,et al. Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[19] B. Isermann,et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. , 1999, Diabetologia.
[20] T. Gilmore,et al. Control of apoptosis by Rel/NF-kappaB transcription factors. , 1999, Oncogene.